Staff Profile: Jennifer L. Kouznetsova

Jennifer L. Kouznetsova, M.S.

Scientific Program Analyst

Division of Preclinical Innovation
Office of the Scientific Director

National Center for Advancing Translational Sciences

National Institutes of Health

Email Jennifer L. Kouznetsova


Jennifer Kouznetsova is a scientific program analyst in the Office of the Scientific Director within NCATS' Division of Preclinical Innovation (DPI). As a scientific administrator for the Quality and Reporting Team, she strives to ensure the quality of science by providing tools and resources to DPI scientists. She also seeks to implement and improve innovative processes to facilitate scientific advancements. During her NCATS tenure, Kouznetsova also has served as a biologist and laboratory manager in the Therapeutics for Rare and Neglected Diseases (TRND) program, where she used her expertise in high-throughput screening and automation to support the TRND mission to speed the development of new treatments for diseases with high unmet medical needs.

Prior to the establishment of NCATS, Kouznetsova was a biologist in the NIH Chemical Genomics Center at the National Human Genome Research Institute, where she specialized in the development, optimization and screening of biochemical, cell-based and high-content assays covering a wide-range of therapeutic indications.

Kouznetsova earned her master’s degree in biotechnology from Johns Hopkins University in Baltimore and her bachelor’s degree in biology from Chatham College in Pittsburgh.

Research Topics

Since joining NCATS, Kouznetsova has collaborated on multidisciplinary teams on a wide variety of projects and initiatives. Seeing the value of team science, Kouznetsova now seeks to develop crosscutting processes and initiatives in support of translational science.

Selected Publications

  1. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen
  2. Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs
  3. Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)
  4. Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum